Lactobacillus acidophilus
ApprovedBiologic
Lactobacillus acidophilus is one of 76 biologic programs targeting Bacterial Vaginosis. It is currently in Approved.
3
Indications
3
Total Trials
0
Active Trials
75
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1053 competitors in Influenza
#DrugCompanyPhaseTrials
1Lactobacillus acidophilus
UUniversiteit Antwerpen
Approved
Fluzone
GSKPreclinical
Crestor
AstraZenecaPreclinical
Trexall
Alnylam PharmaceuticalsPreclinical
Avigan
AAppili Therapeutics Inc.
Preclinical
COMIRNATY
PfizerPreclinical
Antihistamine
Arrowhead PharmaceuticalsPreclinical
Focetria
CChiltern Pesquisa Clinica Ltda
Preclinical
Influenza A/H5N1
NNational Institute of Allergy and Infectious Diseases (NIAID)
Preclinical
TUDCA (tauroursodeoxycholic Acid) Supplementation
TTongji Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Colorectal Cancer1 trial
Comparison of Probiotic Effects on the Outcomes of Patients After Colorectal Cancer Surgery
Completed·—·Phase 4·NCT07144475·90 enrolled
Influenza1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Lactobacillus acidophilus. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Approved[1]
- Company
- UUniversiteit Antwerpen